Foghorn Therapeutics Inc., a pharmaceutical company based in Cambridge, United States, operates within the health care sector, focusing on the discovery and development of innovative drugs aimed at addressing cancer and other serious medical conditions. The company is listed on the Nasdaq stock exchange and primarily serves patients within the United States. As of August 4, 2026, the close price of Foghorn Therapeutics’ stock was recorded at $4.88. The company’s stock has experienced fluctuations over the past year, with a 52-week high of $6.95 on January 12, 2026, and a 52-week low of $3.27 on November 3, 2025.
Foghorn Therapeutics Inc. has a market capitalization of approximately $285,349,664 USD. The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -3.91, reflecting its current earnings status. This negative P/E ratio suggests that the company is not currently generating profits, which is not uncommon for companies in the pharmaceutical sector that are heavily invested in research and development.
The company’s strategic focus on developing novel therapeutics for cancer and other critical health issues positions it within a vital segment of the health care industry. Foghorn Therapeutics’ commitment to innovation and patient care is evident in its ongoing efforts to bring new treatments to market. For more detailed information about their operations and developments, stakeholders and interested parties can visit their official website at www.foghorntx.com .
As Foghorn Therapeutics continues to navigate the competitive landscape of the pharmaceutical industry, its ability to advance its drug pipeline and achieve regulatory milestones will be crucial in determining its future financial performance and market position.
